Advanced search
1 file | 1.90 MB Add to list

Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer

Sarah Piron (UGent) , Jeroen Verhoeven (UGent) , Emma De Coster (UGent) , Benedicte Descamps (UGent) , Ken Kersemans (UGent) , Leen Pieters (UGent) , Anne Vral (UGent) , Christian Vanhove (UGent) and Filip De Vos (UGent)
Author
Organization
Abstract
This two-part preclinical study aims to evaluate prostate specific membrane antigen (PSMA) as a valuable target for expression-based imaging applications and to determine changes in target binding in function of varying apparent molar activities (MA(app)) of [F-18]AlF-PSMA-11. For the evaluation of PSMA expression levels, male NOD/SCID mice bearing prostate cancer (PCa) xenografts of C4-2 (PSMA+++), 22Rv1 (PSMA+) and PC-3 (PSMA-) were administered [F-18]AlF-PSMA-11 with a medium MA(app) (20.24 +/- 3.22 MBq/nmol). SUVmean and SUVmax values were respectively 3.22 and 3.17 times higher for the high versus low PSMA expressing tumors (p < 0.0001). To evaluate the effect of varying MA(app), C4-2 and 22Rv1 xenograft bearing mice underwent additional [F-18]AlF-PSMA-11 imaging with a high (211.2 +/- 38.9 MBq/nmol) and/or low MA(app) (1.92 +/- 0.27 MBq/nmol). SUV values showed a significantly increasing trend with higher MA(app). Significant changes were found for SUVmean and SUVmax between the high versus low MA(app) and medium versus low MA(app) (both p < 0.05), but not between the high versus medium MA(app) (p = 0.055 and 0.25, respectively). The effect of varying MA(app) was more pronounced in low expressing tumors and PSMA expressing tissues (e.g. salivary glands and kidneys). Overall, administration of a high MA(app) increases the detection of low expression tumors while also increasing uptake in PSMA expressing tissues, possibly leading to false positive findings. In radioligand therapy, a medium MA(app) could reduce radiation exposure to dose-limiting organs with only limited effect on radionuclide accumulation in the tumor.
Keywords
Multidisciplinary, MEMBRANE ANTIGEN-EXPRESSION, RADIOLIGAND THERAPY

Downloads

  • s41598-021-02104-6.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.90 MB

Citation

Please use this url to cite or link to this publication:

MLA
Piron, Sarah, et al. “Impact of the Molar Activity and PSMA Expression Level on [18F]AlF-PSMA-11 Uptake in Prostate Cancer.” SCIENTIFIC REPORTS, vol. 11, no. 1, 2021, doi:10.1038/s41598-021-02104-6.
APA
Piron, S., Verhoeven, J., De Coster, E., Descamps, B., Kersemans, K., Pieters, L., … De Vos, F. (2021). Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer. SCIENTIFIC REPORTS, 11(1). https://doi.org/10.1038/s41598-021-02104-6
Chicago author-date
Piron, Sarah, Jeroen Verhoeven, Emma De Coster, Benedicte Descamps, Ken Kersemans, Leen Pieters, Anne Vral, Christian Vanhove, and Filip De Vos. 2021. “Impact of the Molar Activity and PSMA Expression Level on [18F]AlF-PSMA-11 Uptake in Prostate Cancer.” SCIENTIFIC REPORTS 11 (1). https://doi.org/10.1038/s41598-021-02104-6.
Chicago author-date (all authors)
Piron, Sarah, Jeroen Verhoeven, Emma De Coster, Benedicte Descamps, Ken Kersemans, Leen Pieters, Anne Vral, Christian Vanhove, and Filip De Vos. 2021. “Impact of the Molar Activity and PSMA Expression Level on [18F]AlF-PSMA-11 Uptake in Prostate Cancer.” SCIENTIFIC REPORTS 11 (1). doi:10.1038/s41598-021-02104-6.
Vancouver
1.
Piron S, Verhoeven J, De Coster E, Descamps B, Kersemans K, Pieters L, et al. Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer. SCIENTIFIC REPORTS. 2021;11(1).
IEEE
[1]
S. Piron et al., “Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer,” SCIENTIFIC REPORTS, vol. 11, no. 1, 2021.
@article{8728405,
  abstract     = {{This two-part preclinical study aims to evaluate prostate specific membrane antigen (PSMA) as a valuable target for expression-based imaging applications and to determine changes in target binding in function of varying apparent molar activities (MA(app)) of [F-18]AlF-PSMA-11. For the evaluation of PSMA expression levels, male NOD/SCID mice bearing prostate cancer (PCa) xenografts of C4-2 (PSMA+++), 22Rv1 (PSMA+) and PC-3 (PSMA-) were administered [F-18]AlF-PSMA-11 with a medium MA(app) (20.24 +/- 3.22 MBq/nmol). SUVmean and SUVmax values were respectively 3.22 and 3.17 times higher for the high versus low PSMA expressing tumors (p < 0.0001). To evaluate the effect of varying MA(app), C4-2 and 22Rv1 xenograft bearing mice underwent additional [F-18]AlF-PSMA-11 imaging with a high (211.2 +/- 38.9 MBq/nmol) and/or low MA(app) (1.92 +/- 0.27 MBq/nmol). SUV values showed a significantly increasing trend with higher MA(app). Significant changes were found for SUVmean and SUVmax between the high versus low MA(app) and medium versus low MA(app) (both p < 0.05), but not between the high versus medium MA(app) (p = 0.055 and 0.25, respectively). The effect of varying MA(app) was more pronounced in low expressing tumors and PSMA expressing tissues (e.g. salivary glands and kidneys). Overall, administration of a high MA(app) increases the detection of low expression tumors while also increasing uptake in PSMA expressing tissues, possibly leading to false positive findings. In radioligand therapy, a medium MA(app) could reduce radiation exposure to dose-limiting organs with only limited effect on radionuclide accumulation in the tumor.}},
  articleno    = {{22623}},
  author       = {{Piron, Sarah and Verhoeven, Jeroen and De Coster, Emma and Descamps, Benedicte and Kersemans, Ken and Pieters, Leen and Vral, Anne and Vanhove, Christian and De Vos, Filip}},
  issn         = {{2045-2322}},
  journal      = {{SCIENTIFIC REPORTS}},
  keywords     = {{Multidisciplinary,MEMBRANE ANTIGEN-EXPRESSION,RADIOLIGAND THERAPY}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{10}},
  title        = {{Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer}},
  url          = {{http://dx.doi.org/10.1038/s41598-021-02104-6}},
  volume       = {{11}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: